Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 171

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch

Psychedelic Policy Briefing: Week of July 6, 2026

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent...

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient...

PT345 – Steve Thayer, Ph.D. – Vital Psychedelic Conversations

Buried Treasure: How Does Psilocybin Reduce Compulsivity?

Field Trip Health Ltd. Schedules Fiscal First Quarter 2023 Conference Call...

Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley...

New 3D Structures of Cannabinoid Receptor Inform Safer Drug Design

PT344 – Susan Beaulieu – Epigenetics, Resilience, and Remembering

MindMed Board of Directors Approves Reverse Share Split

COMPASS Pathways plc announces second quarter 2022 financial results and business...

Load more

EDITOR PICKS

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data;...

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27...

Psychedelic Policy Briefing: Week of July 6, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©